Molecular basis of PCSK9 function
- PMID: 18649882
- DOI: 10.1016/j.atherosclerosis.2008.06.010
Molecular basis of PCSK9 function
Abstract
The LDL receptor (LDLr) inhibitor Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) has emerged as a genetically validated target for lowering plasma LDL cholesterol levels. In 2007, PCSK9 was found to act as a chaperone that binds the LDLr, thereby targeting it for lysosomal degradation. The enzymatic activity of PCSK9 is not involved in that process, but rather permits proper intramolecular processing of PCSK9. This was demonstrated by both site directed mutagenesis and independent reports of the PCSK9 crystal structure. These reports also elucidated the mode of action of several naturally occurring mutants of PCSK9 associated with hyper- or hypocholesterolemia. The present review summarizes studies published or in print before May 2008 investigating the functional significance of PCSK9 and its promising aspects as a prognostic tool and a drug target.
Similar articles
-
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.Traffic. 2007 Jun;8(6):718-32. doi: 10.1111/j.1600-0854.2007.00562.x. Epub 2007 Apr 25. Traffic. 2007. PMID: 17461796
-
Unravelling the functional significance of PCSK9.Curr Opin Lipidol. 2007 Jun;18(3):304-9. doi: 10.1097/MOL.0b013e3281338531. Curr Opin Lipidol. 2007. PMID: 17495605 Review.
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):835-43. doi: 10.1016/j.numecd.2011.06.002. Epub 2011 Sep 23. Nutr Metab Cardiovasc Dis. 2011. PMID: 21943799 Review.
-
Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.Drug News Perspect. 2008 Jul-Aug;21(6):323-30. doi: 10.1358/dnp.2008.21.6.1246795. Drug News Perspect. 2008. PMID: 18836590 Review.
-
An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.J Mol Biol. 2014 Feb 20;426(4):843-52. doi: 10.1016/j.jmb.2013.11.011. Epub 2013 Nov 16. J Mol Biol. 2014. PMID: 24252255
Cited by
-
Adaptive genetic variation and heart disease risk.Curr Opin Lipidol. 2010 Apr;21(2):116-22. doi: 10.1097/MOL.0b013e3283378e42. Curr Opin Lipidol. 2010. PMID: 20154611 Free PMC article. Review.
-
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity.Cells. 2022 Dec 19;11(24):4132. doi: 10.3390/cells11244132. Cells. 2022. PMID: 36552895 Free PMC article. Review.
-
The evolution of domain arrangements in proteins and interaction networks.Cell Mol Life Sci. 2005 Feb;62(4):435-45. doi: 10.1007/s00018-004-4416-1. Cell Mol Life Sci. 2005. PMID: 15719170 Review.
-
Xanthohumol Pyrazole Derivative Improves Diet-Induced Obesity and Induces Energy Expenditure in High-Fat Diet-Fed Mice.ACS Pharmacol Transl Sci. 2021 Nov 4;4(6):1782-1793. doi: 10.1021/acsptsci.1c00161. eCollection 2021 Dec 10. ACS Pharmacol Transl Sci. 2021. PMID: 34927010 Free PMC article.
-
The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (Cajanus cajan (L.) Millsp.) Leaves on Regulating LDLR and PCSK9 Expression in HepG2 Cells.Molecules. 2019 Jan 30;24(3):493. doi: 10.3390/molecules24030493. Molecules. 2019. PMID: 30704067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous